Sign Out
EMEND is given for 3 days as part of a regimen that includes a corticosteroid and a 5-HT3 antagonist. The package insert for the co-administered 5-HT3 antagonist must be consulted prior to initiation of treatment with EMEND. The recommended dose of EMEND is 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) and 80 mg orally once daily in the morning on Days 2 and 3.
Recommended dosing for the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy: See Table 1.
Click on icon to see table/diagram/imageRecommended dosing for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy: See Table 2.
Click on icon to see table/diagram/imageSee Interactions for additional information on the administration of EMEND with corticosteroids.
Refer to the full prescribing information for co-administered antiemetic agents.
EMEND may be taken with or without food.
No dosage adjustment is necessary based on age, gender, race or Body Mass Index (BMI).
No dosage adjustment is necessary for patients with severe renal insufficiency (creatinine clearance <30 mL/min) or for patients with end stage renal disease undergoing hemodialysis.
No dosage adjustment is necessary for patients with mild to moderate hepatic insufficiency (Child-Pugh score 5 to 9). There are no clinical data in patients with severe hepatic insufficiency (Child-Pugh score >9).
